nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—THRB—thyroid cancer	0.0157	0.0784	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—EPOR—thyroid cancer	0.0157	0.0781	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—EPOR—thyroid cancer	0.0108	0.0538	CbGpPWpGaD
Rasagiline—BCL2—neck—thyroid cancer	0.0106	0.317	CbGeAlD
Rasagiline—BCL2—EPO signaling pathway—EPO—thyroid cancer	0.00706	0.0352	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—RXRA—thyroid cancer	0.00668	0.0333	CbGpPWpGaD
Rasagiline—BCL2—thyroid gland—thyroid cancer	0.00504	0.151	CbGeAlD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—EPO—thyroid cancer	0.00486	0.0242	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—CDK1—thyroid cancer	0.00472	0.0235	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TCF7L1—thyroid cancer	0.00461	0.023	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—BRAF—thyroid cancer	0.00453	0.0226	CbGpPWpGaD
Rasagiline—BCL2—head—thyroid cancer	0.00447	0.134	CbGeAlD
Rasagiline—BCL2—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.00426	0.0213	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—PPARG—thyroid cancer	0.00422	0.021	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—TERT—thyroid cancer	0.00391	0.0195	CbGpPWpGaD
Rasagiline—MAOB—saliva-secreting gland—thyroid cancer	0.00344	0.103	CbGeAlD
Rasagiline—BCL2—lymph node—thyroid cancer	0.00313	0.0937	CbGeAlD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00286	0.0142	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—LAMA2—thyroid cancer	0.00261	0.013	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00261	0.013	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.0026	0.013	CbGpPWpGaD
Rasagiline—BCL2—Activation of BAD and translocation to mitochondria—AKT1—thyroid cancer	0.00259	0.0129	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00255	0.0127	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—TP53—thyroid cancer	0.00254	0.0127	CbGpPWpGaD
Rasagiline—MAOB—thyroid gland—thyroid cancer	0.0021	0.0628	CbGeAlD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—thyroid cancer	0.00204	0.0102	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—PTEN—thyroid cancer	0.0019	0.00947	CbGpPWpGaD
Rasagiline—MAOB—head—thyroid cancer	0.00186	0.0557	CbGeAlD
Rasagiline—BCL2—Estrogen signaling pathway—AKT1—thyroid cancer	0.00184	0.00917	CbGpPWpGaD
Rasagiline—BCL2—Activation of BH3-only proteins—AKT1—thyroid cancer	0.00172	0.00858	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PTEN—thyroid cancer	0.00169	0.00841	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—HRAS—thyroid cancer	0.0016	0.00797	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—KRAS—thyroid cancer	0.00157	0.00785	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CCND1—thyroid cancer	0.00156	0.00776	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—RXRA—thyroid cancer	0.00152	0.00756	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—BRAF—thyroid cancer	0.00149	0.00745	CbGpPWpGaD
Rasagiline—CYP1A2—thyroid gland—thyroid cancer	0.00149	0.0447	CbGeAlD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CCND1—thyroid cancer	0.00148	0.00736	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—thyroid cancer	0.00146	0.00727	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—thyroid cancer	0.00146	0.00727	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—NRAS—thyroid cancer	0.00144	0.00717	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00136	0.00675	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—BRAF—thyroid cancer	0.00134	0.0067	CbGpPWpGaD
Rasagiline—MAOB—lymph node—thyroid cancer	0.0013	0.039	CbGeAlD
Rasagiline—BCL2—C-MYB transcription factor network—PTGS2—thyroid cancer	0.0013	0.00647	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—thyroid cancer	0.0013	0.00646	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—HRAS—thyroid cancer	0.00129	0.00641	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—AKT1—thyroid cancer	0.00126	0.00627	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—thyroid cancer	0.00124	0.00618	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—thyroid cancer	0.00124	0.00617	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—AKT1—thyroid cancer	0.00123	0.00614	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.00119	0.00593	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—AKT1—thyroid cancer	0.00118	0.00589	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CCND1—thyroid cancer	0.00117	0.00585	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—thyroid cancer	0.00114	0.00567	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—AKT1—thyroid cancer	0.00114	0.00566	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—MINPP1—thyroid cancer	0.00111	0.00555	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—thyroid cancer	0.0011	0.00549	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—AKT1—thyroid cancer	0.00109	0.00546	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—AKT1—thyroid cancer	0.00109	0.00546	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—thyroid cancer	0.00105	0.00525	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—AKT1—thyroid cancer	0.00102	0.00509	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—NRAS—thyroid cancer	0.00101	0.00504	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.00101	0.00501	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—AKT1—thyroid cancer	0.001	0.00501	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000998	0.0013	CcSEcCtD
Rasagiline—Hypertonia—Epirubicin—thyroid cancer	0.000994	0.0013	CcSEcCtD
Rasagiline—Vaginal infection—Doxorubicin—thyroid cancer	0.000991	0.00129	CcSEcCtD
Rasagiline—Neuropathy—Doxorubicin—thyroid cancer	0.000986	0.00129	CcSEcCtD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—thyroid cancer	0.000981	0.00489	CbGpPWpGaD
Rasagiline—Dyspnoea—Sorafenib—thyroid cancer	0.000976	0.00127	CcSEcCtD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—thyroid cancer	0.000973	0.00485	CbGpPWpGaD
Rasagiline—Nausea—Vandetanib—thyroid cancer	0.000964	0.00126	CcSEcCtD
Rasagiline—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000964	0.00126	CcSEcCtD
Rasagiline—Dyspepsia—Sorafenib—thyroid cancer	0.000964	0.00126	CcSEcCtD
Rasagiline—Oesophagitis—Doxorubicin—thyroid cancer	0.000959	0.00125	CcSEcCtD
Rasagiline—Phlebitis—Epirubicin—thyroid cancer	0.000956	0.00125	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—thyroid cancer	0.000953	0.00475	CbGpPWpGaD
Rasagiline—Decreased appetite—Sorafenib—thyroid cancer	0.000952	0.00124	CcSEcCtD
Rasagiline—Thrombophlebitis—Epirubicin—thyroid cancer	0.000951	0.00124	CcSEcCtD
Rasagiline—Ecchymosis—Doxorubicin—thyroid cancer	0.000949	0.00124	CcSEcCtD
Rasagiline—Mouth ulceration—Doxorubicin—thyroid cancer	0.000949	0.00124	CcSEcCtD
Rasagiline—Neoplasm—Doxorubicin—thyroid cancer	0.000949	0.00124	CcSEcCtD
Rasagiline—MAOB—Metabolism—NDUFA13—thyroid cancer	0.000947	0.00472	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—thyroid cancer	0.000947	0.00472	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000946	0.00123	CcSEcCtD
Rasagiline—Constipation—Sorafenib—thyroid cancer	0.000937	0.00122	CcSEcCtD
Rasagiline—Vascular purpura—Epirubicin—thyroid cancer	0.000921	0.0012	CcSEcCtD
Rasagiline—Hypertonia—Doxorubicin—thyroid cancer	0.00092	0.0012	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—thyroid cancer	0.000919	0.00458	CbGpPWpGaD
Rasagiline—Eczema—Epirubicin—thyroid cancer	0.000916	0.0012	CcSEcCtD
Rasagiline—Eye pain—Epirubicin—thyroid cancer	0.000912	0.00119	CcSEcCtD
Rasagiline—BCL2—Immune System—RAP1GAP—thyroid cancer	0.000902	0.0045	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000896	0.00117	CcSEcCtD
Rasagiline—Renal failure acute—Epirubicin—thyroid cancer	0.000892	0.00116	CcSEcCtD
Rasagiline—MAOB—Metabolism—CHST14—thyroid cancer	0.000891	0.00444	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—AKT1—thyroid cancer	0.00089	0.00444	CbGpPWpGaD
Rasagiline—Phlebitis—Doxorubicin—thyroid cancer	0.000885	0.00115	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—LGALS3—thyroid cancer	0.000882	0.0044	CbGpPWpGaD
Rasagiline—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00088	0.00115	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PRKAR1A—thyroid cancer	0.000875	0.00436	CbGpPWpGaD
Rasagiline—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000873	0.00114	CcSEcCtD
Rasagiline—Urticaria—Sorafenib—thyroid cancer	0.00087	0.00114	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—thyroid cancer	0.00087	0.00433	CbGpPWpGaD
Rasagiline—Abdominal pain—Sorafenib—thyroid cancer	0.000866	0.00113	CcSEcCtD
Rasagiline—Body temperature increased—Sorafenib—thyroid cancer	0.000866	0.00113	CcSEcCtD
Rasagiline—BCL2—Kit receptor signaling pathway—AKT1—thyroid cancer	0.000866	0.00432	CbGpPWpGaD
Rasagiline—Dermatitis bullous—Epirubicin—thyroid cancer	0.000862	0.00112	CcSEcCtD
Rasagiline—Purpura—Epirubicin—thyroid cancer	0.000854	0.00112	CcSEcCtD
Rasagiline—Vascular purpura—Doxorubicin—thyroid cancer	0.000852	0.00111	CcSEcCtD
Rasagiline—Eczema—Doxorubicin—thyroid cancer	0.000848	0.00111	CcSEcCtD
Rasagiline—Eye pain—Doxorubicin—thyroid cancer	0.000844	0.0011	CcSEcCtD
Rasagiline—Cardiac failure—Epirubicin—thyroid cancer	0.000844	0.0011	CcSEcCtD
Rasagiline—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00084	0.0011	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—BRAF—thyroid cancer	0.000837	0.00417	CbGpPWpGaD
Rasagiline—Renal failure acute—Doxorubicin—thyroid cancer	0.000825	0.00108	CcSEcCtD
Rasagiline—Diplopia—Epirubicin—thyroid cancer	0.000824	0.00108	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000824	0.00108	CcSEcCtD
Rasagiline—Osteoarthritis—Epirubicin—thyroid cancer	0.000824	0.00108	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NRAS—thyroid cancer	0.00082	0.00409	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000815	0.00406	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000811	0.00404	CbGpPWpGaD
Rasagiline—Migraine—Epirubicin—thyroid cancer	0.000811	0.00106	CcSEcCtD
Rasagiline—Affect lability—Epirubicin—thyroid cancer	0.000811	0.00106	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000808	0.00105	CcSEcCtD
Rasagiline—Hypersensitivity—Sorafenib—thyroid cancer	0.000807	0.00105	CcSEcCtD
Rasagiline—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000797	0.00104	CcSEcCtD
Rasagiline—Face oedema—Epirubicin—thyroid cancer	0.000795	0.00104	CcSEcCtD
Rasagiline—Purpura—Doxorubicin—thyroid cancer	0.000791	0.00103	CcSEcCtD
Rasagiline—Asthenia—Sorafenib—thyroid cancer	0.000786	0.00103	CcSEcCtD
Rasagiline—Cardiac failure—Doxorubicin—thyroid cancer	0.000781	0.00102	CcSEcCtD
Rasagiline—Mood swings—Epirubicin—thyroid cancer	0.00078	0.00102	CcSEcCtD
Rasagiline—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000778	0.00102	CcSEcCtD
Rasagiline—Pruritus—Sorafenib—thyroid cancer	0.000775	0.00101	CcSEcCtD
Rasagiline—Ataxia—Epirubicin—thyroid cancer	0.000774	0.00101	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—thyroid cancer	0.000773	0.00385	CbGpPWpGaD
Rasagiline—Diplopia—Doxorubicin—thyroid cancer	0.000762	0.000995	CcSEcCtD
Rasagiline—Osteoarthritis—Doxorubicin—thyroid cancer	0.000762	0.000995	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000762	0.000995	CcSEcCtD
Rasagiline—Liver function test abnormal—Epirubicin—thyroid cancer	0.00076	0.000993	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—PTEN—thyroid cancer	0.000753	0.00375	CbGpPWpGaD
Rasagiline—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000752	0.000982	CcSEcCtD
Rasagiline—Migraine—Doxorubicin—thyroid cancer	0.00075	0.000979	CcSEcCtD
Rasagiline—Affect lability—Doxorubicin—thyroid cancer	0.00075	0.000979	CcSEcCtD
Rasagiline—Diarrhoea—Sorafenib—thyroid cancer	0.000749	0.000978	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—thyroid cancer	0.000739	0.00368	CbGpPWpGaD
Rasagiline—Face oedema—Doxorubicin—thyroid cancer	0.000736	0.00096	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000734	0.00366	CbGpPWpGaD
Rasagiline—Muscular weakness—Epirubicin—thyroid cancer	0.000726	0.000948	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—thyroid cancer	0.000725	0.00361	CbGpPWpGaD
Rasagiline—Dizziness—Sorafenib—thyroid cancer	0.000724	0.000946	CcSEcCtD
Rasagiline—Mood swings—Doxorubicin—thyroid cancer	0.000722	0.000942	CcSEcCtD
Rasagiline—MAOB—Metabolism—HPGD—thyroid cancer	0.000718	0.00358	CbGpPWpGaD
Rasagiline—Ataxia—Doxorubicin—thyroid cancer	0.000717	0.000935	CcSEcCtD
Rasagiline—Dysphagia—Epirubicin—thyroid cancer	0.000712	0.000929	CcSEcCtD
Rasagiline—Influenza—Epirubicin—thyroid cancer	0.000712	0.000929	CcSEcCtD
Rasagiline—Asthma—Epirubicin—thyroid cancer	0.000712	0.000929	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000708	0.00353	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—thyroid cancer	0.000706	0.00352	CbGpPWpGaD
Rasagiline—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000704	0.000918	CcSEcCtD
Rasagiline—Vomiting—Sorafenib—thyroid cancer	0.000696	0.000909	CcSEcCtD
Rasagiline—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000696	0.000909	CcSEcCtD
Rasagiline—Angina pectoris—Epirubicin—thyroid cancer	0.000693	0.000905	CcSEcCtD
Rasagiline—Rash—Sorafenib—thyroid cancer	0.000691	0.000902	CcSEcCtD
Rasagiline—Dermatitis—Sorafenib—thyroid cancer	0.00069	0.000901	CcSEcCtD
Rasagiline—Headache—Sorafenib—thyroid cancer	0.000686	0.000896	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000673	0.00335	CbGpPWpGaD
Rasagiline—Muscular weakness—Doxorubicin—thyroid cancer	0.000672	0.000877	CcSEcCtD
Rasagiline—Dysuria—Epirubicin—thyroid cancer	0.000666	0.000869	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000662	0.000864	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000661	0.00329	CbGpPWpGaD
Rasagiline—Influenza—Doxorubicin—thyroid cancer	0.000659	0.00086	CcSEcCtD
Rasagiline—Asthma—Doxorubicin—thyroid cancer	0.000659	0.00086	CcSEcCtD
Rasagiline—Dysphagia—Doxorubicin—thyroid cancer	0.000659	0.00086	CcSEcCtD
Rasagiline—Pollakiuria—Epirubicin—thyroid cancer	0.000658	0.000858	CcSEcCtD
Rasagiline—BCL2—Apoptosis—AKT1—thyroid cancer	0.000653	0.00325	CbGpPWpGaD
Rasagiline—Nausea—Sorafenib—thyroid cancer	0.000651	0.000849	CcSEcCtD
Rasagiline—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00065	0.000848	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—thyroid cancer	0.000646	0.00322	CbGpPWpGaD
Rasagiline—Weight decreased—Epirubicin—thyroid cancer	0.000644	0.000841	CcSEcCtD
Rasagiline—Angina pectoris—Doxorubicin—thyroid cancer	0.000642	0.000838	CcSEcCtD
Rasagiline—Infestation—Epirubicin—thyroid cancer	0.000635	0.000829	CcSEcCtD
Rasagiline—Infestation NOS—Epirubicin—thyroid cancer	0.000635	0.000829	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—thyroid cancer	0.000627	0.00313	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000622	0.000812	CcSEcCtD
Rasagiline—Stomatitis—Epirubicin—thyroid cancer	0.000619	0.000808	CcSEcCtD
Rasagiline—Jaundice—Epirubicin—thyroid cancer	0.000619	0.000808	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—thyroid cancer	0.000618	0.00308	CbGpPWpGaD
Rasagiline—Conjunctivitis—Epirubicin—thyroid cancer	0.000617	0.000805	CcSEcCtD
Rasagiline—Dysuria—Doxorubicin—thyroid cancer	0.000616	0.000804	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000612	0.000799	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—CCND1—thyroid cancer	0.000611	0.00304	CbGpPWpGaD
Rasagiline—Sweating—Epirubicin—thyroid cancer	0.000608	0.000794	CcSEcCtD
Rasagiline—Pollakiuria—Doxorubicin—thyroid cancer	0.000608	0.000794	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000608	0.00303	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—AKT1—thyroid cancer	0.000607	0.00302	CbGpPWpGaD
Rasagiline—Haematuria—Epirubicin—thyroid cancer	0.000605	0.00079	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CDK1—thyroid cancer	0.000603	0.003	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000601	0.000785	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—thyroid cancer	0.0006	0.00299	CbGpPWpGaD
Rasagiline—Epistaxis—Epirubicin—thyroid cancer	0.000599	0.000782	CcSEcCtD
Rasagiline—Weight decreased—Doxorubicin—thyroid cancer	0.000596	0.000778	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PTEN—thyroid cancer	0.000589	0.00294	CbGpPWpGaD
Rasagiline—Infestation NOS—Doxorubicin—thyroid cancer	0.000587	0.000767	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—thyroid cancer	0.000587	0.000767	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000587	0.00293	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA2—thyroid cancer	0.00058	0.00289	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000576	0.000752	CcSEcCtD
Rasagiline—Haemoglobin—Epirubicin—thyroid cancer	0.000573	0.000748	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—thyroid cancer	0.000572	0.000747	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—thyroid cancer	0.000572	0.000747	CcSEcCtD
Rasagiline—Rhinitis—Epirubicin—thyroid cancer	0.000571	0.000746	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—thyroid cancer	0.000571	0.000745	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—thyroid cancer	0.00057	0.000744	CcSEcCtD
Rasagiline—Hypoaesthesia—Epirubicin—thyroid cancer	0.000567	0.00074	CcSEcCtD
Rasagiline—Sweating—Doxorubicin—thyroid cancer	0.000563	0.000735	CcSEcCtD
Rasagiline—Urinary tract disorder—Epirubicin—thyroid cancer	0.000563	0.000735	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—thyroid cancer	0.000561	0.000733	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—thyroid cancer	0.00056	0.000731	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—thyroid cancer	0.00056	0.000731	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—thyroid cancer	0.000558	0.000729	CcSEcCtD
Rasagiline—Epistaxis—Doxorubicin—thyroid cancer	0.000554	0.000723	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000544	0.00271	CbGpPWpGaD
Rasagiline—Eye disorder—Epirubicin—thyroid cancer	0.000532	0.000695	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—thyroid cancer	0.00053	0.000692	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—thyroid cancer	0.00053	0.00264	CbGpPWpGaD
Rasagiline—Cardiac disorder—Epirubicin—thyroid cancer	0.000529	0.00069	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—thyroid cancer	0.000529	0.00069	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—thyroid cancer	0.000527	0.000688	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000525	0.000685	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000521	0.00068	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—thyroid cancer	0.000519	0.000678	CcSEcCtD
Rasagiline—BCL2—Immune System—TPR—thyroid cancer	0.000518	0.00258	CbGpPWpGaD
Rasagiline—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000518	0.000676	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—thyroid cancer	0.000517	0.000675	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—thyroid cancer	0.000517	0.000675	CcSEcCtD
Rasagiline—Immune system disorder—Epirubicin—thyroid cancer	0.000515	0.000672	CcSEcCtD
Rasagiline—BCL2—Immune System—LGALS3—thyroid cancer	0.000514	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—thyroid cancer	0.000514	0.00256	CbGpPWpGaD
Rasagiline—Mediastinal disorder—Epirubicin—thyroid cancer	0.000513	0.00067	CcSEcCtD
Rasagiline—Chills—Epirubicin—thyroid cancer	0.000511	0.000667	CcSEcCtD
Rasagiline—BCL2—Immune System—PRKAR1A—thyroid cancer	0.00051	0.00254	CbGpPWpGaD
Rasagiline—Alopecia—Epirubicin—thyroid cancer	0.000503	0.000657	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000501	0.0025	CbGpPWpGaD
Rasagiline—Mental disorder—Epirubicin—thyroid cancer	0.000499	0.000652	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—thyroid cancer	0.000496	0.000648	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—thyroid cancer	0.000493	0.000643	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—thyroid cancer	0.000489	0.000639	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—thyroid cancer	0.000489	0.000638	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—thyroid cancer	0.000486	0.000634	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NRG1—thyroid cancer	0.000484	0.00241	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000483	0.00241	CbGpPWpGaD
Rasagiline—Back pain—Epirubicin—thyroid cancer	0.00048	0.000626	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—thyroid cancer	0.000478	0.000624	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—thyroid cancer	0.000477	0.000623	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—thyroid cancer	0.000476	0.000622	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000475	0.00062	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—thyroid cancer	0.000473	0.00236	CbGpPWpGaD
Rasagiline—Chills—Doxorubicin—thyroid cancer	0.000473	0.000618	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000468	0.00233	CbGpPWpGaD
Rasagiline—Alopecia—Doxorubicin—thyroid cancer	0.000466	0.000608	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—thyroid cancer	0.000462	0.000603	CcSEcCtD
Rasagiline—Ill-defined disorder—Epirubicin—thyroid cancer	0.00046	0.000601	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—thyroid cancer	0.000459	0.000599	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—thyroid cancer	0.000458	0.000598	CcSEcCtD
Rasagiline—Agitation—Epirubicin—thyroid cancer	0.000456	0.000595	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—thyroid cancer	0.000452	0.00059	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000451	0.00225	CbGpPWpGaD
Rasagiline—Dysgeusia—Doxorubicin—thyroid cancer	0.000449	0.000587	CcSEcCtD
Rasagiline—Malaise—Epirubicin—thyroid cancer	0.000447	0.000584	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—thyroid cancer	0.000446	0.000582	CcSEcCtD
Rasagiline—Syncope—Epirubicin—thyroid cancer	0.000445	0.000581	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—thyroid cancer	0.000444	0.00058	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—thyroid cancer	0.000444	0.00058	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—thyroid cancer	0.000441	0.000576	CcSEcCtD
Rasagiline—Loss of consciousness—Epirubicin—thyroid cancer	0.000436	0.000569	CcSEcCtD
Rasagiline—Cough—Epirubicin—thyroid cancer	0.000433	0.000565	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—thyroid cancer	0.00043	0.000561	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—thyroid cancer	0.000428	0.000559	CcSEcCtD
Rasagiline—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000426	0.000556	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—thyroid cancer	0.000424	0.000554	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—thyroid cancer	0.000422	0.000551	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—thyroid cancer	0.000422	0.000551	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—thyroid cancer	0.000422	0.000551	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—thyroid cancer	0.000421	0.000549	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000419	0.000547	CcSEcCtD
Rasagiline—Discomfort—Epirubicin—thyroid cancer	0.000417	0.000545	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—thyroid cancer	0.000414	0.00054	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—thyroid cancer	0.000413	0.000539	CcSEcCtD
Rasagiline—MAOB—Metabolism—TPR—thyroid cancer	0.000412	0.00206	CbGpPWpGaD
Rasagiline—Vertigo—Doxorubicin—thyroid cancer	0.000412	0.000538	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—thyroid cancer	0.000412	0.000537	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—thyroid cancer	0.000411	0.000536	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000408	0.00203	CbGpPWpGaD
Rasagiline—Confusional state—Epirubicin—thyroid cancer	0.000408	0.000533	CcSEcCtD
Rasagiline—MAOB—Metabolism—PRKAR1A—thyroid cancer	0.000406	0.00202	CbGpPWpGaD
Rasagiline—Loss of consciousness—Doxorubicin—thyroid cancer	0.000403	0.000527	CcSEcCtD
Rasagiline—Infection—Epirubicin—thyroid cancer	0.000402	0.000525	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000401	0.002	CbGpPWpGaD
Rasagiline—Cough—Doxorubicin—thyroid cancer	0.0004	0.000523	CcSEcCtD
Rasagiline—BCL2—Apoptosis—AKT1—thyroid cancer	0.0004	0.00199	CbGpPWpGaD
Rasagiline—Shock—Epirubicin—thyroid cancer	0.000398	0.00052	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—thyroid cancer	0.000398	0.000519	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—thyroid cancer	0.000397	0.000518	CcSEcCtD
Rasagiline—Hypertension—Doxorubicin—thyroid cancer	0.000396	0.000517	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—thyroid cancer	0.000393	0.000513	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—thyroid cancer	0.000391	0.000511	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—thyroid cancer	0.000391	0.00051	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—thyroid cancer	0.000391	0.00051	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00039	0.00194	CbGpPWpGaD
Rasagiline—Anxiety—Doxorubicin—thyroid cancer	0.000389	0.000508	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000388	0.000507	CcSEcCtD
Rasagiline—Discomfort—Doxorubicin—thyroid cancer	0.000386	0.000504	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—thyroid cancer	0.000386	0.000504	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—HRAS—thyroid cancer	0.000385	0.00192	CbGpPWpGaD
Rasagiline—Dry mouth—Doxorubicin—thyroid cancer	0.000382	0.000499	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—thyroid cancer	0.000378	0.000494	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—thyroid cancer	0.000378	0.000493	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000373	0.00186	CbGpPWpGaD
Rasagiline—Infection—Doxorubicin—thyroid cancer	0.000372	0.000486	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000369	0.000481	CcSEcCtD
Rasagiline—Shock—Doxorubicin—thyroid cancer	0.000368	0.000481	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—thyroid cancer	0.000367	0.00048	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—thyroid cancer	0.000366	0.000478	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—thyroid cancer	0.000364	0.000475	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—thyroid cancer	0.000363	0.000475	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000362	0.000473	CcSEcCtD
Rasagiline—Dyspnoea—Epirubicin—thyroid cancer	0.000361	0.000471	CcSEcCtD
Rasagiline—Somnolence—Epirubicin—thyroid cancer	0.00036	0.00047	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—thyroid cancer	0.000357	0.000466	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—thyroid cancer	0.000356	0.000465	CcSEcCtD
Rasagiline—Decreased appetite—Epirubicin—thyroid cancer	0.000352	0.000459	CcSEcCtD
Rasagiline—BCL2—Immune System—CDK1—thyroid cancer	0.000351	0.00175	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.000351	0.00175	CbGpPWpGaD
Rasagiline—Hypotension—Doxorubicin—thyroid cancer	0.00035	0.000457	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000349	0.000456	CcSEcCtD
Rasagiline—Constipation—Epirubicin—thyroid cancer	0.000346	0.000452	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000341	0.000445	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—AKT1—thyroid cancer	0.00034	0.00169	CbGpPWpGaD
Rasagiline—Insomnia—Doxorubicin—thyroid cancer	0.000339	0.000442	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000338	0.00169	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA2—thyroid cancer	0.000338	0.00168	CbGpPWpGaD
Rasagiline—Paraesthesia—Doxorubicin—thyroid cancer	0.000336	0.000439	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000335	0.00167	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—thyroid cancer	0.000334	0.000436	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—thyroid cancer	0.000334	0.000435	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—thyroid cancer	0.000333	0.000435	CcSEcCtD
Rasagiline—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000331	0.000432	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—thyroid cancer	0.00033	0.00043	CcSEcCtD
Rasagiline—Decreased appetite—Doxorubicin—thyroid cancer	0.000326	0.000425	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000323	0.000422	CcSEcCtD
Rasagiline—Urticaria—Epirubicin—thyroid cancer	0.000322	0.00042	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—thyroid cancer	0.00032	0.000418	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—thyroid cancer	0.00032	0.000418	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—thyroid cancer	0.00032	0.000418	CcSEcCtD
Rasagiline—MAOB—Metabolism—SLC5A5—thyroid cancer	0.000309	0.00154	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—thyroid cancer	0.000309	0.000403	CcSEcCtD
Rasagiline—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000306	0.0004	CcSEcCtD
Rasagiline—Hypersensitivity—Epirubicin—thyroid cancer	0.000298	0.000389	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—thyroid cancer	0.000298	0.000388	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—thyroid cancer	0.000296	0.000387	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—thyroid cancer	0.000296	0.000387	CcSEcCtD
Rasagiline—Asthenia—Epirubicin—thyroid cancer	0.00029	0.000379	CcSEcCtD
Rasagiline—Pruritus—Epirubicin—thyroid cancer	0.000286	0.000374	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000285	0.00142	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRG1—thyroid cancer	0.000282	0.0014	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—thyroid cancer	0.000277	0.000362	CcSEcCtD
Rasagiline—Hypersensitivity—Doxorubicin—thyroid cancer	0.000276	0.00036	CcSEcCtD
Rasagiline—Asthenia—Doxorubicin—thyroid cancer	0.000269	0.000351	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—thyroid cancer	0.000268	0.000349	CcSEcCtD
Rasagiline—Pruritus—Doxorubicin—thyroid cancer	0.000265	0.000346	CcSEcCtD
Rasagiline—MAOB—Metabolism—RXRA—thyroid cancer	0.000259	0.00129	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MINPP1—thyroid cancer	0.000258	0.00129	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—thyroid cancer	0.000257	0.000336	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—thyroid cancer	0.000256	0.000335	CcSEcCtD
Rasagiline—Rash—Epirubicin—thyroid cancer	0.000255	0.000333	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—thyroid cancer	0.000255	0.000333	CcSEcCtD
Rasagiline—Headache—Epirubicin—thyroid cancer	0.000254	0.000331	CcSEcCtD
Rasagiline—Dizziness—Doxorubicin—thyroid cancer	0.000248	0.000323	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PTEN—thyroid cancer	0.000242	0.00121	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—thyroid cancer	0.00024	0.000314	CcSEcCtD
Rasagiline—Vomiting—Doxorubicin—thyroid cancer	0.000238	0.000311	CcSEcCtD
Rasagiline—Rash—Doxorubicin—thyroid cancer	0.000236	0.000308	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—thyroid cancer	0.000236	0.000308	CcSEcCtD
Rasagiline—Headache—Doxorubicin—thyroid cancer	0.000235	0.000306	CcSEcCtD
Rasagiline—Nausea—Doxorubicin—thyroid cancer	0.000222	0.00029	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—NDUFA13—thyroid cancer	0.000219	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NRAS—thyroid cancer	0.000216	0.00108	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CHST14—thyroid cancer	0.000206	0.00103	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—thyroid cancer	0.000186	0.000928	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPGD—thyroid cancer	0.000166	0.000828	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARG—thyroid cancer	0.000164	0.000816	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—thyroid cancer	0.000158	0.000788	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—thyroid cancer	0.000141	0.000704	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—thyroid cancer	0.00014	0.000696	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000135	0.000672	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—thyroid cancer	0.000129	0.000642	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—thyroid cancer	0.000126	0.000628	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—thyroid cancer	0.000112	0.00056	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—thyroid cancer	0.000108	0.00054	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TPR—thyroid cancer	9.54e-05	0.000476	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	9.39e-05	0.000468	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—thyroid cancer	9.21e-05	0.000459	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	8.51e-05	0.000424	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—thyroid cancer	8.14e-05	0.000405	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC5A5—thyroid cancer	7.14e-05	0.000356	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.69e-05	0.000334	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—thyroid cancer	6.48e-05	0.000323	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RXRA—thyroid cancer	6e-05	0.000299	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.84e-05	0.000291	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—thyroid cancer	3.79e-05	0.000189	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—thyroid cancer	2.98e-05	0.000149	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—thyroid cancer	2.6e-05	0.00013	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—thyroid cancer	1.5e-05	7.47e-05	CbGpPWpGaD
